J&J, Actelion Pharamceuticals confirm early talks for reported potential acquisition

NEW BRUNSWICK, N.J. — On Nov. 25, Bloomberg reported that Johnson & Johnson and Actelion Pharmaceuticals were in discussion over a potential acquisition of Actelion by J&J. Both companies have confirmed that they are in preliminary discussions. 

 

“There can be no assurance any transaction will result from these discussions,” J&J said in a statement. “Johnson & Johnson does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.”